

Jan-Willem C Alffenaar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/814848/publications.pdf>

Version: 2024-02-01

281
papers

9,285
citations

47006

47
h-index

64796

79
g-index

285
all docs

285
docs citations

285
times ranked

7207
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. <i>Archives of Disease in Childhood</i> , 2022, 107, 70-77.	1.9	16
2	Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	2.4	23
3	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 466-473.	3.0	6
4	Therapeutic Drug Monitoring of Ganciclovir: Where Are We?. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 138-147.	2.0	19
5	Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 3-10.	2.0	8
6	Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 198-214.	2.0	14
7	A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries. <i>Pulmonology</i> , 2022, 28, 44-58.	2.1	10
8	Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China. <i>European Respiratory Journal</i> , 2022, 59, 2101925.	6.7	18
9	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. <i>Clinical Infectious Diseases</i> , 2022, 74, 2252-2260.	5.8	14
10	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	3.2	4
11	Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. <i>Journal of Medical Internet Research</i> , 2022, 24, e33062.	4.3	32
12	Paediatric Acute Respiratory Distress Syndrome Neuromuscular Blockade study (PAN-study): a phase IV randomised controlled trial of early neuromuscular blockade in moderate-to-severe paediatric acute respiratory distress syndrome. <i>Trials</i> , 2022, 23, 96.	1.6	0
13	Real-World Effects of Antibiotic Treatment on Acute COPD Exacerbations in Outpatients: A Cohort Study under the PharmLines Initiative. <i>Respiration</i> , 2022, 101, 553-564.	2.6	0
14	Dosing of vancomycin and target attainment in neonates: a systematic review. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106515.	2.5	5
15	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	6.7	11
16	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 121-132.	2.0	18
17	Barriers to Optimal Tuberculosis Treatment Services at Community Health Centers: A Qualitative Study From a High Prevalent Tuberculosis Country. <i>Frontiers in Pharmacology</i> , 2022, 13, 857783.	3.5	7
18	Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). <i>BMJ Open</i> , 2022, 12, e054788.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
20	Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals. <i>Internal Medicine Journal</i> , 2022, 52, 1135-1143.	0.8	11
21	An Audit to Evaluate Vancomycin Therapeutic Drug Monitoring in a Neonatal Intensive Care Unit. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 651-658.	2.0	3
22	Precision Therapy for Invasive Fungal Diseases. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 18.	3.5	4
23	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
24	Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	5
25	Clinical standards for the dosing and management of TB drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 483-499.	1.2	22
26	Clinical standards for drug-susceptible pulmonary TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 592-604.	1.2	6
27	Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. <i>Clinical Infectious Diseases</i> , 2021, 73, e3520-e3528.	5.8	27
28	Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China. <i>European Respiratory Journal</i> , 2021, 57, 2003463.	6.7	9
29	Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 23-39.	3.3	27
30	Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1347-1358.	2.4	13
31	A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 423-429.	3.0	16
32	Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities. <i>European Respiratory Journal</i> , 2021, 57, 2002349.	6.7	6
33	Measuring anti-TB drug concentrations in hair: unlocking the door to cumulative drug exposure and treatment outcome. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 3-5.	1.2	1
34	Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 310-321.	2.0	44
35	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 943-953.	3.5	5
36	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	15

#	ARTICLE	IF	CITATIONS
37	Saliva-based linezolid monitoring on a mobile UV spectrophotometer. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1786-1792.	3.0	10
38	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021, 60, 685-710.	3.5	39
39	<i>Mycobacterium tuberculosis</i> sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. <i>International Journal of Infectious Diseases</i> , 2021, 104, 680-684.	3.3	7
40	Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1547-1552.	3.0	13
41	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. <i>Clinical Pharmacokinetics</i> , 2021, 60, 711-725.	3.5	23
42	From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 928-941.	4.7	131
43	Predictive Performance of Bayesian Vancomycin Monitoring in the Critically Ill*. <i>Critical Care Medicine</i> , 2021, 49, e952-e960.	0.9	13
44	Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study. <i>BMJ Open</i> , 2021, 11, e041521.	1.9	8
45	Investigator-Initiated Studies in Infectious Diseases—Considerations for Pharmacokinetic-Pharmacodynamic Optimization. <i>Clinical Infectious Diseases</i> , 2021, 73, 1742.	5.8	0
46	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021, 10, 2089.	2.4	14
47	Reply to Van Daele et al., “Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?”. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1
48	Cefdinir and Î²-Lactamase Inhibitor Independent Efficacy Against <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Pharmacology</i> , 2021, 12, 677005.	3.5	12
49	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
50	Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106443.	2.5	13
51	Does Chemotherapy-Induced Gastrointestinal Mucositis Affect the Bioavailability and Efficacy of Anti-Infective Drugs?. <i>Biomedicines</i> , 2021, 9, 1389.	3.2	1
52	Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: a qualitative study from the patient’s perspective. <i>BMC Public Health</i> , 2021, 21, 1903.	2.9	27
53	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 37-66.	0.8	24
54	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. <i>BMJ Open</i> , 2021, 11, e049777.	1.9	4

#	ARTICLE	IF	CITATIONS
55	A simple HPLC-UV Method for Therapeutic Drug Monitoring of Linezolid in human Plasma in low-resourced settings. <i>Journal of Applied Bioanalysis</i> , 2021, 7, e21008-e21008.	0.2	2
56	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1774-1780.	5.8	59
57	Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2238-2239.	5.8	4
58	Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 55, 1901908.	6.7	11
59	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 83-92.	2.0	59
60	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106180.	2.5	17
61	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133
62	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	15
63	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	2.6	15
64	Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1158, 122397.	2.3	17
65	Intermittent regimens for tuberculosis treatment: Back to the Future?. <i>European Respiratory Journal</i> , 2020, 56, 2002510.	6.7	0
66	Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000606.	3.0	5
67	Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
68	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. <i>Intensive Care Medicine</i> , 2020, 46, 1127-1153.	8.2	504
69	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. <i>European Respiratory Journal</i> , 2020, 56, 2000803.	6.7	8
70	Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review. <i>BMJ Open</i> , 2020, 10, e034940.	1.9	2
71	Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 21.	2.6	53
72	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. <i>European Respiratory Journal</i> , 2020, 56, 2001086.	6.7	3

#	ARTICLE	IF	CITATIONS
73	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	6.7	273
74	Delamanid Resistance: Update and Clinical Management. <i>Clinical Infectious Diseases</i> , 2020, 71, 3252-3259.	5.8	30
75	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	1.9	4
76	Challenging the management of drug-resistant tuberculosis. <i>Lancet, The</i> , 2020, 395, 783.	13.7	10
77	Commemorating World TB Day 2020: "It's TIME" It's time to End the Global TB Epidemic. <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
78	Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 894.	3.5	11
79	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
80	Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 899-910.	3.5	12
81	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 726-729.	3.0	8
82	Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?. <i>International Journal of Infectious Diseases</i> , 2020, 92, S5-S9.	3.3	13
83	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. <i>European Respiratory Journal</i> , 2020, 55, 1901903.	6.7	12
84	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126
85	Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 3529-3537.	4.7	19
86	Cross-validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Levofloxacin in Saliva. <i>Journal of Applied Bioanalysis</i> , 2020, 6, 68-70.	0.2	2
87	Patients and Medical Staff Attitudes Toward the Future Inclusion of eHealth in Tuberculosis Management: Perspectives From Six Countries Evaluated using a Qualitative Framework. <i>JMIR MHealth and UHealth</i> , 2020, 8, e18156.	3.7	5
88	Influence of age on real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000535.	3.0	3
89	Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. <i>Journal of Infection</i> , 2019, 78, 35-39.	3.3	30
90	Performance of a web-based application measuring spot quality in dried blood spot sampling. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1846-1853.	2.3	14

#	ARTICLE	IF	CITATIONS
91	Repurposed Oral Ribavirin for Respiratory Virus Infections Requires Pharmacokinetic-pharmacodynamic Dose Optimization. <i>Clinical Infectious Diseases</i> , 2019, 70, 1258.	5.8	1
92	In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00483.	2.4	10
93	Management of patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 645-662.	1.2	55
94	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. <i>European Respiratory Journal</i> , 2019, 54, 1901522.	6.7	113
95	Continuous versus intermittent infusion of cefotaxime in critically ill patients: a randomized controlled trial comparing plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 441-448.	3.0	5
96	Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2848-2864.	3.0	7
97	Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. <i>Mycoses</i> , 2019, 62, 698-705.	4.0	17
98	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. <i>International Journal of Infectious Diseases</i> , 2019, 83, 72-76.	3.3	41
99	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
100	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1445-1454.	3.5	19
101	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. <i>European Respiratory Journal</i> , 2019, 54, 1900373.	6.7	7
102	Acquired Drug Resistance: Recognizing the Potential of Repurposed Drugs. <i>Clinical Infectious Diseases</i> , 2019, 69, 2038-2039.	5.8	4
103	A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects. <i>Bioanalysis</i> , 2019, 11, 495-508.	1.5	43
104	Tuberculosis-Related Malnutrition: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 340-341.	4.0	19
105	Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1407-1417.	2.4	12
106	Comment on: The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 834-834.	3.0	1
107	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
108	Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. <i>European Respiratory Journal</i> , 2019, 54, 1901402.	6.7	11

#	ARTICLE	IF	CITATIONS
109	Clinical application of a dried blood spot assay for sirolimus and everolimus in transplant patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1854-1862.	2.3	24
110	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 59-65.	2.0	5
111	Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 714-718.	2.0	13
112	Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 409-430.	2.0	188
113	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019, 54, 1900580.	6.7	21
114	Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?. <i>European Respiratory Journal</i> , 2019, 54, 1901508.	6.7	5
115	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S560-S561.	0.9	0
116	Therapeutic Drug Monitoring: The Need for Practical Guidance. <i>Clinical Infectious Diseases</i> , 2019, 68, 1065-1066.	5.8	21
117	Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 691-698.	3.0	3
118	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 747-766.	3.5	53
119	Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 3-4.	9.1	0
120	Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	10
121	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
122	The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. <i>Drugs</i> , 2019, 79, 161-171.	10.9	61
123	Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2019, 53, 1802107.	6.7	13
124	Posaconazole trough concentrations are not influenced by inflammation: A prospective study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 325-329.	2.5	9
125	Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs. <i>Clinical Mass Spectrometry</i> , 2019, 14, 34-45.	1.9	17
126	Antituberculosis Drug-induced Liver Injury in Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 50-53.	2.0	12

#	ARTICLE	IF	CITATIONS
127	Predictors for treatment outcomes among patients with drug-susceptible tuberculosis in the Netherlands: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2019, 25, 761.e1-761.e7.	6.0	14
128	Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	8
129	Lack of penetration of amikacin into saliva of tuberculosis patients. <i>European Respiratory Journal</i> , 2018, 51, 1702024.	6.7	9
130	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702490.	6.7	7
131	Pound foolish and penny wise“when will dosing of rifampicin be optimised?. <i>Lancet Respiratory Medicine</i> , 2018, 6, e11-e12.	10.7	11
132	<i>In Vitro</i> Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	22
133	Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. <i>Clinical Infectious Diseases</i> , 2018, 66, 1625-1630.	5.8	131
134	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. <i>Clinical Infectious Diseases</i> , 2018, 67, 1743-1749.	5.8	19
135	Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2305-2313.	3.0	71
136	Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702187.	6.7	1
137	Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1755-1762.	3.0	32
138	Risk factors contributing to a low darunavir plasma concentration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 456-461.	2.4	4
139	Antifungal PK/PD in the Critically Ill. , 2018, , 213-238.		1
140	New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	13.6	55
141	Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 17-37.	2.0	37
142	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S327-S335.	5.8	53
143	Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. <i>Clinical Infectious Diseases</i> , 2018, 67, S267-S273.	5.8	26
144	<i>in vitro</i> -Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. <i>Clinical Infectious Diseases</i> , 2018, 67, S308-S316.	5.8	45

#	ARTICLE	IF	CITATIONS
145	Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2018, 67, S303-S307.	5.8	26
146	Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. <i>BMJ Open</i> , 2018, 8, e023899.	1.9	7
147	Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 2-2.	1.2	4
148	Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. <i>Journal of Infection</i> , 2018, 77, 469-478.	3.3	114
149	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
150	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	13.7	452
151	The association between the <i>NAT2</i> genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2747-2760.	2.4	42
152	Invasive Candidiasis in the Elderly: Considerations for Drug Therapy. <i>Drugs and Aging</i> , 2018, 35, 781-789.	2.7	16
153	Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	8
154	Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 109-113.	2.5	18
155	Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 991-999.	1.2	0
156	Simple and robust LC-MS/MS analysis method for therapeutic drug monitoring of micafungin. <i>Bioanalysis</i> , 2018, 10, 877-886.	1.5	9
157	Global TB Network: working together to eliminate tuberculosis. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 347-349.	0.7	18
158	Determination of levofloxacin in human serum using liquid chromatography tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2018, 4, 16-25.	0.2	9
159	Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in Indonesian tuberculosis patients. <i>International Journal of Mycobacteriology</i> , 2018, 7, 380.	0.6	12
160	Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	42
161	Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	10
162	Target attainment with continuous dosing of piperacillin/tazobactam in critical illness: a prospective observational study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 68-73.	2.5	12

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
164	Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. <i>European Respiratory Journal</i> , 2017, 49, 1700387.	6.7	233
165	Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1700173.	6.7	14
166	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	6.7	16
167	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601724.	6.7	20
168	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	2.5	35
169	Dried blood spot validation of five immunosuppressants, without hematocrit correction, on two LC-MS/MS systems. <i>Bioanalysis</i> , 2017, 9, 553-563.	1.5	42
170	Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	33
171	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 898.	9.1	9
172	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2325-2329.	2.4	5
173	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
174	Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3292-3293.	3.9	12
175	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	23
176	Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 1727-1733.	1.0	49
177	Low Caspofungin Exposure in Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
178	Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 11-21.	4.4	19
179	Voriconazole metabolism is influenced by severe inflammation: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 261-267.	3.0	113
180	Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. <i>Clinical Infectious Diseases</i> , 2017, 64, 104-105.	5.8	36

#	ARTICLE	IF	CITATIONS
181	Bioavailability of voriconazole in hospitalised patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 243-246.	2.5	19
182	The effect of inflammation on voriconazole trough concentrations in children. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 678-680.	2.4	16
183	Treatment of <i>Mycobacterium avium</i> –“intracellulare complex: a great leap forward. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i1-i2.	3.0	1
184	Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2017, 23, 1718-1721.	4.3	43
185	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2016, 62, civ921.	5.8	38
186	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C₂h₂ measurements. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1695-1696.	1.2	3
187	Alternative Sampling Strategies for Therapeutic Drug Monitoring. , 2016, , 279-336.		12
188	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. <i>PLoS ONE</i> , 2016, 11, e0149768.	2.5	25
189	Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. <i>PLoS ONE</i> , 2016, 11, e0166030.	2.5	6
190	Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4646-4651.	3.2	11
191	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. <i>European Respiratory Journal</i> , 2016, 48, 1800-1802.	6.7	9
192	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2691-2703.	3.0	28
193	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1288-1290.	6.7	12
194	Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3942-3947.	3.2	12
195	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3193-3195.	3.2	23
196	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2336-2342.	3.2	29
197	Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?. <i>European Respiratory Journal</i> , 2016, 48, 1230-1233.	6.7	5
198	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. <i>International Journal of Mycobacteriology</i> , 2016, 5, S44-S45.	0.6	11

#	ARTICLE	IF	CITATIONS
199	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. <i>European Respiratory Journal</i> , 2016, 48, 1237-1239.	6.7	8
200	Sertraline for HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1111.	9.1	2
201	Comment on: Utility of voriconazole therapeutic drug monitoring: a meta-analysis: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3316-3317.	3.0	8
202	Statin Adjunctive Therapy for Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7004-7004.	3.2	7
203	Therapeutic Drug Monitoring of Posaconazole: an Update. <i>Current Fungal Infection Reports</i> , 2016, 10, 51-61.	2.6	126
204	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016, 48, 932-934.	6.7	8
205	Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1025-1037.	3.1	19
206	Reply to Verhaeghe et al: Table 1. <i>Clinical Infectious Diseases</i> , 2016, 63, 146-147.	5.8	0
207	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 703-710.	3.0	41
208	Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 533-544.	3.3	52
209	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. <i>European Respiratory Journal</i> , 2016, 47, 1867-1869.	6.7	59
210	Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2727-2731.	3.2	51
211	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 34-40.	11.4	40
212	Emerging drugs and alternative possibilities in the treatment of tuberculosis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 103-116.	2.4	12
213	End TB with precision treatment!. <i>European Respiratory Journal</i> , 2016, 47, 680-682.	6.7	45
214	Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 509-521.	3.3	62
215	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 47, 1229-1234.	6.7	30
216	Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 766-771.	2.0	29

#	ARTICLE	IF	CITATIONS
217	What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis?. <i>Bioanalysis</i> , 2015, 7, 345-351.	1.5	59
218	Evaluation of macrolides for possible use against multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2015, 46, 444-455.	6.7	20
219	Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. <i>International Journal of Infectious Diseases</i> , 2015, 32, 101-104.	3.3	36
220	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. <i>European Respiratory Journal</i> , 2015, 45, 569-571.	6.7	20
221	Quantification of co-trimoxazole in serum and plasma using MS/MS. <i>Bioanalysis</i> , 2015, 7, 2741-2749.	1.5	3
222	An interlaboratory quality control programme for the measurement of tuberculosis drugs. <i>European Respiratory Journal</i> , 2015, 46, 268-271.	6.7	27
223	Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1177-1181.	3.2	10
224	Acquired Drug Resistance: We Can Do More Than We Think!. <i>Clinical Infectious Diseases</i> , 2015, 60, 969-970.	5.8	17
225	Dried blood spot analysis of creatinine with LC-MS/MS in addition to immunosuppressants analysis. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1585-1594.	3.7	46
226	Breakpoints and Drug Exposure Are Inevitably Closely Linked. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1384-1384.	3.2	5
227	Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5675-5680.	3.2	28
228	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4907-4913.	3.2	37
229	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	6.7	47
230	The performance of five different dried blood spot cards for the analysis of six immunosuppressants. <i>Bioanalysis</i> , 2015, 7, 1225-1235.	1.5	36
231	Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples. <i>Bioanalysis</i> , 2015, 7, 481-495.	1.5	21
232	The Never Ending Struggle Against Development of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015, 61, 137-138.	5.8	0
233	Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2474-2474.	3.2	7
234	Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 332-337.	2.5	28

#	ARTICLE	IF	CITATIONS
235	The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis. <i>Bioanalysis</i> , 2015, 7, 1717-1722.	1.5	13
236	Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry. <i>Journal of Applied Bioanalysis</i> , 2015, 1, 89-98.	0.2	16
237	Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method. <i>Bioanalysis</i> , 2014, 6, 2125-2133.	1.5	35
238	Clinical Validation of the Analysis of Fluconazole in Oral Fluid in Hospitalized Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6742-6746.	3.2	10
239	Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 304-308.	3.2	24
240	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
241	Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS. <i>Talanta</i> , 2014, 121, 9-17.	5.5	62
242	Inflammation Is Associated with Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7098-7101.	3.2	81
243	Insufficient Fluconazole Exposure in Pediatric Cancer Patients and the Need for Therapeutic Drug Monitoring in Critically Ill Children. <i>Clinical Infectious Diseases</i> , 2014, 59, 1527-1533.	5.8	27
244	Raltegravir and rifampicin in patients with HIV and tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1046-1047.	9.1	3
245	Quantification and Validation of Ertapenem Using a Liquid Chromatography-Tandem Mass Spectrometry Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3481-3484.	3.2	14
246	In vitro synergy between linezolid and clarithromycin against <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2014, 44, 808-811.	6.7	14
247	Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2988-2994.	3.0	29
248	Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014, 43, 884-897.	6.7	55
249	Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 229-234.	2.5	68
250	Trimethoprim/sulfamethoxazole susceptibility of <i>Mycobacterium tuberculosis</i> . <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 472-474.	2.5	14
251	Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 917-918, 1-4.	2.3	32
252	Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. <i>Talanta</i> , 2013, 115, 47-54.	5.5	110

#	ARTICLE	IF	CITATIONS
253	Simultaneous Quantification of Anidulafungin and Caspofungin in Plasma by an Accurate and Simple Liquid Chromatography Tandem Mass-Spectrometric Method. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 778-784.	2.0	14
254	Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 504-512.	6.7	55
255	Dried Blood Spot Analysis Suitable for Therapeutic Drug Monitoring of Voriconazole, Fluconazole, and Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4999-5004.	3.2	45
256	Drug concentration in lung tissue in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 1750-1752.	6.7	23
257	Clinical Validation of the Analysis of Linezolid and Clarithromycin in Oral Fluid of Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3676-3680.	3.2	23
258	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2013, 42, 1614-1621.	6.7	59
259	Dried Blood Spot Analysis Combined With Limited Sampling Models Can Advance Therapeutic Drug Monitoring of Tuberculosis Drugs. <i>Journal of Infectious Diseases</i> , 2012, 205, 1765-1766.	4.0	13
260	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5758-5763.	3.2	67
261	Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction. <i>Transplant Infectious Disease</i> , 2012, 14, 440-443.	1.7	14
262	Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 350-354.	2.0	30
263	Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1063-1070.	2.3	117
264	Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization. <i>Current Pharmaceutical Design</i> , 2011, 17, 2931-2939.	1.9	72
265	Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1287-1289.	3.2	59
266	Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach. <i>Current Pharmaceutical Design</i> , 2011, 17, 2900-2930.	1.9	26
267	Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. <i>European Respiratory Journal</i> , 2011, 38, 888-894.	6.7	70
268	Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 97-101.	2.0	55
269	Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 39-44.	2.3	89
270	Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for <i>Mycobacterium ulcerans</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3878-3883.	3.2	49

#	ARTICLE	IF	CITATIONS
271	Clarithromycin Significantly Increases Linezolid Serum Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5418-5419.	3.2	31
272	Determination of Moxifloxacin in Human Plasma, Plasma Ultrafiltrate, and Cerebrospinal Fluid by a Rapid and Simple Liquid Chromatography-Tandem Mass Spectrometry Method. <i>Journal of Analytical Toxicology</i> , 2010, 34, 135-141.	2.8	52
273	Intravenous Voriconazole after Toxic Oral Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2741-2742.	3.2	11
274	Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients. <i>Clinical Pharmacokinetics</i> , 2010, 49, 559-565.	3.5	50
275	Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 49, 1080-1082.	5.8	91
276	Omeprazole Significantly Reduces Posaconazole Serum Trough Level. <i>Clinical Infectious Diseases</i> , 2009, 48, 839-839.	5.8	50
277	High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 262-263.	2.4	22
278	Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1771-1777.	2.3	51
279	Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents. <i>Clinical Infectious Diseases</i> , 2009, 48, 1441-1458.	5.8	368
280	Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2008, 12, 967-71.	1.2	20
281	Monitoring during and after tuberculosis treatment. , 0, , 308-325.		1